Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in
patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly …

Deep brain stimulation via implanted electrodes can alleviate neuronal disorders. However,
its applicability is constrained by side effects resulting from the insertion of electrodes into …

Focused ultrasound (FUS) is a disruptive medical technology, and its implementation in the
clinic represents the culmination of decades of research. Lying at the convergence of …

In the past decade, evidence for a fluid clearance pathway in the central nervous system
known as the glymphatic system has grown. According to the glymphatic system concept …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Background Low-intensity pulsed ultrasound with concomitant administration of intravenous
microbubbles (LIPU-MB) can be used to open the blood–brain barrier. We aimed to assess …

The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper,
reflecting the unique requirements of the brain. In this review, following a brief historical …

MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately
and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the …